-
1.
公开(公告)号:US20210038545A1
公开(公告)日:2021-02-11
申请号:US16965663
申请日:2019-01-30
申请人: NSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE) , INSTITUT PASTEUR DE LILLE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG , UNIVERSITÉ DE LILLE
发明人: François TROTTEIN , Adeline BARTHELEMY , Valentin SENCIO , Mauro Martins TEIXEIRA , Angelica THOMAZ VIEIRA , Luciana TAVARES
摘要: Severe influenza is associated with defects in pulmonary innate immunity, a phenomenon leading to secondary bacterial infections. The gut microbiota can control immune/inflammatory responses locally and at distant sites. The inventors hypothesized that perturbation of the gut microbiota during severe influenza might participate in bacterial superinfection post-influenza. Their data demonstrated that influenza infection profoundly altered the functionality of the gut microbiota as assessed by the altered production of short chain fatty acids (SCFAs). Remarkably, treatment of colonized (IAV microbiota) mice or IAV-infected mice with acetate, the main SCFA found systematically, reinforced host defenses against S. pneumoniae. The present invention thus relates to the use of short-chain fatty acids for the treatment of bacterial superinfections post-influenza.